Top

Published in:

01-07-2005 | Correspondence

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK

Author: Eduardo Carracedo-Martínez

Published in: PharmacoEconomics | Issue 7/2005

Excerpt

An economic evaluation of etoricoxib versus non-selective NSAIDs has been published recently by Moore et al.[1] The decision tree of this study considers the possibility of non-selective NSAIDs plus gastroprotective agents as a decision arm, but not etoricoxib plus gastroprotective agents. …

Moore A, Phillips C, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004; 22 (10): 643–60PubMedCrossRef

Singh G. Understanding NSAID-PPI-COX-2 interrelationships. Drugs Today (Barc) 2004; 40 Suppl. A: 21–4

Kimmey MB, Lanas A. Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-in-flammatory drugs and COX-2 selective inhibitors. Aliment Pharmacol Ther 2004; 19 Suppl. 1: 60–5PubMedCrossRef

Lee MC, Lee S, Suh DC, et al. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea. Curr Med Res Opin 2003; 19 (7): 597–602PubMedCrossRef

Bouee S, Charlemagne A, Fagnani F, et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine 2004; 71: 214–20PubMedCrossRef

Ofman JJ, Badamgarav E, Henning JM, et al. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. Am J Med 2004; 116 (12):835–42PubMedCrossRef

Teeling M, Bennett K, Feely J. Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Br J Clin Pharmacol 2004; 57 (3): 337–43PubMedCrossRef

Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003; 49: 283–92PubMedCrossRef

Title: Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK
Author: Eduardo Carracedo-Martínez
Publication date: 01-07-2005
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 7/2005
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200523070-00008

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2005

Introducing economic evaluation as a policy tool in Korea: Will decision makers get quality information?

The state of patient-reported outcomes in atrial fibrillation

Costs and medical care consequences associated with the diagnosis of peripheral arterial disease

Discounting health effects in pharmacoeconomic evaluations

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

Evaluating health-related quality-of-life studies in paediatric populations